Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics

TARO POWR Grades

• Sentiment is the dimension where TARO ranks best; there it ranks ahead of 94.64% of US stocks.
• TARO's strongest trending metric is Value; it's been moving down over the last 179 days.
• TARO's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

TARO Stock Summary

• With a price/earnings ratio of 1,515.89, Taro Pharmaceutical Industries Ltd P/E ratio is greater than that of about 99.38% of stocks in our set with positive earnings.
• Of note is the ratio of Taro Pharmaceutical Industries Ltd's sales and general administrative expense to its total operating expenses; merely 15.4% of US stocks have a lower such ratio.
• For TARO, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
• Stocks that are quantitatively similar to TARO, based on their financial statements, market capitalization, and price volatility, are ABCM, FTEK, NLST, TCX, and MELI.
• Visit TARO's SEC page to see the company's official filings. To visit the company's web site, go to www.taro.com.

TARO Valuation Summary

• In comparison to the median Healthcare stock, TARO's price/sales ratio is 15.79% higher, now standing at 4.4.
• TARO's price/earnings ratio has moved up 82 over the prior 243 months.
• Over the past 243 months, TARO's price/sales ratio has gone up 2.2.

Below are key valuation metrics over time for TARO.

TARO Growth Metrics

Its 5 year revenue growth rate is now at -32.18%.
• The 5 year net income to common stockholders growth rate now stands at -54.85%.
• Its year over year net income to common stockholders growth rate is now at -258.31%.

TARO's revenue has moved down $384,320,000 over the prior 70 months.

The table below shows TARO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	566.431	-148.901	1.077
2021-09-30	567.592	85.894	7.683
2021-06-30	578.449	25.653	29.498
2021-03-31	548.97	45.77	-386.653
2021-03-31	548.97	45.77	-386.653
2020-12-31	575.562	NA	-302.671

TARO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• TARO has a Quality Grade of B, ranking ahead of 81% of graded US stocks.
• TARO's asset turnover comes in at 0.239 -- ranking 182nd of 682 Pharmaceutical Products stocks.
• ELTP, ADMP, and ENTA are the stocks whose asset turnover ratios are most correlated with TARO.

The table below shows TARO's key quality metrics over time.